| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/24/2011 | US20110046067 COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USE |
| 02/24/2011 | US20110046066 Inhibitors of iap |
| 02/24/2011 | US20110046042 Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof |
| 02/24/2011 | US20110046005 Method and nucleic acids for the analysis of colon cell proliferative disorders |
| 02/24/2011 | US20110045589 Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells |
| 02/24/2011 | US20110045106 Coffee extract |
| 02/24/2011 | US20110045102 Cancer chemotherapy compositions comprising PI3K pathway modulators and triptolide |
| 02/24/2011 | US20110045094 Encapsulated quantum dot |
| 02/24/2011 | US20110045092 Casein particles encapsulating therapeutically active agents and uses thereof |
| 02/24/2011 | US20110045091 Anti-angiogenesis, anticancer proliferation properties of lymphocytic-derived microparticles |
| 02/24/2011 | US20110045080 Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
| 02/24/2011 | US20110045076 Linear order release polymer |
| 02/24/2011 | US20110045060 Kit for detecting cancer cells metastasizing into sentinel lymph node |
| 02/24/2011 | US20110045057 Virosomes Comprising Hemagglutinin Derived from an Influenza Virus Produced in a Cell Line, Compositions, Methods of Manufacturing, Use Thereof |
| 02/24/2011 | US20110045049 Immunomodulating compositions and methods of use |
| 02/24/2011 | US20110045046 Glycopeptides and methods of making and using them |
| 02/24/2011 | US20110045031 Use of Buckysome or Carbon Nanotube for Drug Delivery |
| 02/24/2011 | US20110045029 Oral formulation for delivery of poorly absorbed drugs |
| 02/24/2011 | US20110045007 Fusion or linked proteins with extended half life |
| 02/24/2011 | US20110045006 LUCA2 and Antibodies That Bind Thereto |
| 02/24/2011 | US20110045005 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/24/2011 | US20110045001 Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
| 02/24/2011 | US20110044998 Stabilized Angiopoietin-2 Antibodies And Uses Thereof |
| 02/24/2011 | US20110044993 Method for the prevention and treatment of cancer by inhibition of gpvi |
| 02/24/2011 | US20110044992 Method of delivering an anti-cancer agent to a cell |
| 02/24/2011 | US20110044991 Methods and compositions for treating lymphoma and myeloma |
| 02/24/2011 | US20110044988 Methods of treatment using anti-mif antibodies |
| 02/24/2011 | US20110044984 Monoclonal Antibody Capable of Binding to Anexelekto, and Use Thereof |
| 02/24/2011 | US20110044983 Complement inhibitors as therapeutic agents for treatment of cancer |
| 02/24/2011 | US20110044977 Subcutaneous anti-HER2 antibody formulations and uses thereof |
| 02/24/2011 | US20110044962 Notch induced natural killer cell generation and therapeutic uses |
| 02/24/2011 | US20110044953 Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies |
| 02/24/2011 | US20110044952 Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
| 02/24/2011 | US20110044949 Oncolytic virus replicating selectively in tumor cells |
| 02/24/2011 | US20110044948 Poxviral oncolytic vectors |
| 02/24/2011 | US20110044946 Genetec regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species |
| 02/24/2011 | US20110044942 Methods of treatment for solid tumors |
| 02/24/2011 | US20110044941 Immunotherapy for reversing immune suppression |
| 02/24/2011 | US20110044940 Thiazole Carboxamide Derivatives and Their Use to Treat Cancer |
| 02/24/2011 | US20110044938 Tetrahydrobenzothiophene derivatives |
| 02/24/2011 | US20110044937 Staged immune-response modulation in oncolytic therapy |
| 02/24/2011 | US20110044931 Multi-conjugate of sirna and preparing method thereof |
| 02/24/2011 | US20110044921 Substances and compositions for enhancing dna repair and methods of use |
| 02/24/2011 | US20110044911 Use of Functionalized Magnetic Nanoparticles in Cancer Detection and Treatment |
| 02/24/2011 | US20110044906 Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer |
| 02/24/2011 | US20110044901 Novel compounds |
| 02/24/2011 | US20110044900 Method for treating and/or diagnosing tumor by gold particles coated with a polymer |
| 02/24/2011 | US20110044899 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| 02/24/2011 | US20110044898 Translocator protein ligands |
| 02/24/2011 | US20110044896 Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
| 02/24/2011 | US20110044895 Methods and compositions for reducing stemness in oncogenesis |
| 02/24/2011 | US20110044894 Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof |
| 02/24/2011 | US20110044893 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/24/2011 | US20110042260 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/24/2011 | US20110042247 Formulations of azacitidine and its derivatives |
| 02/24/2011 | DE112008003232T5 Antigen-Bindungskonstrukte Antigen-binding constructs |
| 02/24/2011 | DE102005062440B4 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen Protein-based carrier system to overcome resistance of tumor cells |
| 02/24/2011 | CA2772240A1 Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| 02/24/2011 | CA2771699A1 Method of treating cancer |
| 02/24/2011 | CA2771630A1 Therapeutic methods and compositions |
| 02/24/2011 | CA2771609A1 Substituted benzoazepines as toll-like receptor modulators |
| 02/24/2011 | CA2771606A1 Methods of using cd44 fusion proteins to treat cancer |
| 02/24/2011 | CA2771594A1 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| 02/24/2011 | CA2771484A1 Substituted benzoazepines as toll-like receptor modulators |
| 02/24/2011 | CA2771445A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 02/24/2011 | CA2771436A1 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| 02/24/2011 | CA2771432A1 Heterocyclic oxime compounds |
| 02/24/2011 | CA2771403A1 Quinoline derivative-containing pharmaceutical composition |
| 02/24/2011 | CA2771234A1 Substituted hydrazide compounds and use thereof |
| 02/24/2011 | CA2771086A1 Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
| 02/23/2011 | EP2287306A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287305A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287285A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/23/2011 | EP2287230A1 Docetaxel polymer derivative, method for producing same and use of same |
| 02/23/2011 | EP2287199A2 Anti-alpha V beta 6 antibodies |
| 02/23/2011 | EP2287198A2 Anti-alpha V beta 6 antibodies |
| 02/23/2011 | EP2287194A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| 02/23/2011 | EP2287192A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 02/23/2011 | EP2287186A1 Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| 02/23/2011 | EP2287183A1 Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity |
| 02/23/2011 | EP2287182A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287181A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287155A1 Acylthiourea compound or salt thereof, and use of the compound or the salt |
| 02/23/2011 | EP2286844A2 Antibody-drug conjugates and methods |
| 02/23/2011 | EP2286843A2 Compounds for targeting endothelial cells |
| 02/23/2011 | EP2286836A1 Immunostimulating agent |
| 02/23/2011 | EP2286832A1 Bacterial compositions for the treatment of cancer |
| 02/23/2011 | EP2286831A1 A method of inducing a CTL response |
| 02/23/2011 | EP2286827A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2011 | EP2286826A2 Treatment of tumor metastase and cancer |
| 02/23/2011 | EP2286818A1 Fulvestrant formulation |
| 02/23/2011 | EP2286812A1 Solubilized topoisomerase poisons |
| 02/23/2011 | EP2286799A2 Microspheres for active embolization |
| 02/23/2011 | EP2286798A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 02/23/2011 | EP2286795A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 02/23/2011 | EP2286794A1 Use of cationic liposomes comprising an active drug |
| 02/23/2011 | EP2285989A2 Novel targets for regulation of angiogenesis |
| 02/23/2011 | EP2285833A1 AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| 02/23/2011 | EP2285817A2 Novel uses of d-mannopyranose derivatives activating angiogenesis |
| 02/23/2011 | EP2285811A1 3-(3-pyrimidin-2-yl-benzyl)-ý1,2,4¨triazoloý4,3-b¨pyridazine derivatives as met kinase inhibitors |